22Jul/13

아스텔라스 면역억제제 '아스타그랍' 승인장기이식 거부반응 효과 …임상 3상 시험 … – 의약뉴스

아스텔라스 면역억제제 ‘아스타그랍’ 승인장기이식 거부반응 효과 …임상 3상 시험
의약뉴스
아스타그랍은 1일 1회 복용하는 경구약으로 바실릭시맙(basiliximab)을 포함하거나 혹은 포함하지 않고 마이코페노레이트 모페틸(mycophenolate mofetil)과 코르티코스테로이드(corticosteroids) 약물과 병용해 이식거부반응을 예방한다. 이번 승인은 1093명의 환자 

22Jul/13

Government conniving with tobacco lobby, norms up in smoke, says SC – The New Indian Express


Economic Times

Government conniving with tobacco lobby, norms up in smoke, says SC
The New Indian Express
High Court,” the Bench added. The counsel who was supposed to appear for the Centre had “some other interest”, the Bench contended. As per the statistics provided by the government of India, nearly 10 lakh people die of lung or oral cancer every year.
SC puts ring around smoking adsDaily News & Analysis
‘Display warning mandatory for tobacco vendors’Hindustan Times
SC tobacco rap on ‘death merchant’ govtCalcutta Telegraph

all 13 news articles »

22Jul/13

U.S. Launch of Astellas' Astagraf XL – Analyst Blog – NASDAQ


MedPage Today

U.S. Launch of Astellas’ Astagraf XL – Analyst Blog
NASDAQ
received approval for Astagraf XL (tacrolimus extended-release capsules) in the U.S. for the prevention of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab
Long-Release Tacrolimus Wins FDA NodMedPage Today
New Treatment Option for Kidney Transplant RecipientsMonthly Prescribing Reference
FDA approves Astellas once-daily organ rejection drugPharmaTimes
Genetic Engineering News –NephrologyNews.com –The Pharma Letter
all 8 news articles »